InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Topline Safety, Efficacy Data for MDD Study
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released positive phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (“MDD”). According to the announcement, study participants experienced a rapid, robust and clinically significant reduction of depression…